F2R and intracranial hemorrhage: Previously, vorapaxar, which is an antagonist of the protease-activated receptor 1 (PAR-1), was believed to be a promising antithrombotic inhibitor with no effect on bleeding.111 However, it was subsequently shown to increase the risk of intracranial haemorrhage.112 Reassuringly, glenzocimab has already been tested in the high-risk setting of stroke treated with thrombolysis, where intracranial haemorrhage is common, and there has been no sign of an increased risk of intracranial haemorrhage with potent GPVI inhibition.24